Dermata Therapeutics (DRMA) Net Cash Flow (2020 - 2026)
Dermata Therapeutics (DRMA) posted quarterly Net Cash Flow of -$576696.0 for Q1 2026, down 108.79% year-over-year from $6.6 million in Q1 2025, and down 120.69% quarter-over-quarter from $2.8 million in Q4 2025.
Dermata Therapeutics (DRMA) Net Cash Flow (2020 - 2026) Analysis & Trends
Dermata Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$576696.0 for Q1 2026.
- In Q1 2026, Net Cash Flow fell 108.79% year-over-year to -$576696.0; the TTM figure through Mar 2026 stood at -$2.8 million (down 156.49% YoY), while the FY2025 annual figure was $4.3 million, up 200.97% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$576696.0, down from $2.8 million in the prior quarter.
- The five-year high for Net Cash Flow was $6.6 million in Q1 2025, with the low at -$3.2 million in Q2 2025.
- The 5-year median for Net Cash Flow is -$576696.0 (2026), against an average of -$229174.4.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow jumped 369.81% in 2022, then slumped 1605.86% in 2025.
- Dermata Therapeutics' Net Cash Flow stood at -$1.8 million in 2022, then surged by 144.19% to $806652.0 in 2023, then sank by 469.7% to -$3.0 million in 2024, then surged by 193.46% to $2.8 million in 2025, then plunged by 120.69% to -$576696.0 in 2026.
- Business Quant data shows DRMA's Net Cash Flow at -$576696.0 in Q1 2026, $2.8 million in Q4 2025, and -$1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Dermata Therapeutics | 5.33 Mn | 5.33 Mn | - | -596,978.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -576,696.00 |
| Mar 31, 2026 | -576,696.00 |
| Dec 31, 2025 | 2.79 Mn |
| Dec 31, 2025 | 2.79 Mn |
| Sep 30, 2025 | -1.81 Mn |
| Sep 30, 2025 | -1.81 Mn |
| Jun 30, 2025 | -3.21 Mn |
| Jun 30, 2025 | -3.21 Mn |
| Mar 31, 2025 | 6.56 Mn |
| Mar 31, 2025 | 6.56 Mn |
| Dec 31, 2024 | -2.98 Mn |
| Dec 31, 2024 | -2.98 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 213,419.00 |
| Jun 30, 2024 | 213,419.00 |
| Mar 31, 2024 | -2.70 Mn |
| Mar 31, 2024 | -2.70 Mn |
| Dec 31, 2023 | 806,652.00 |
| Dec 31, 2023 | 806,652.00 |